Previous Page  207 / 1816 Next Page
Information
Show Menu
Previous Page 207 / 1816 Next Page
Page Background

Who decides?

Low risk:

the same in NL, UK, B, It, D, …?

Countries with 5 y endocrine therapy for ALL ER+



Countries with endocrine therapy starting at intermediate

risk

(≥ 5% recurrence or survival benefit)

Side effects:

Very (too?) well documented and known for RT

Emerging knowledge for systemic therapy…

RT after tumorectomy: not always required?

Less local treatment: The role of RT in BCT